Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Total Non-Current Liabilities (2016 - 2025)

Intellia Therapeutics (NTLA) has disclosed Total Non-Current Liabilities for 9 consecutive years, with $170.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Non-Current Liabilities fell 46.49% to $170.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $170.7 million, a 46.49% decrease, with the full-year FY2025 number at $170.7 million, down 46.49% from a year prior.
  • Total Non-Current Liabilities was $170.7 million for Q4 2025 at Intellia Therapeutics, down from $319.1 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $319.1 million in Q4 2024 to a low of $170.7 million in Q4 2025.
  • A 5-year average of $236.8 million and a median of $238.1 million in 2022 define the central range for Total Non-Current Liabilities.
  • Peak YoY movement for Total Non-Current Liabilities: grew 27.21% in 2024, then tumbled 46.49% in 2025.
  • Intellia Therapeutics' Total Non-Current Liabilities stood at $254.2 million in 2021, then rose by 2.47% to $260.5 million in 2022, then fell by 3.72% to $250.8 million in 2023, then grew by 27.21% to $319.1 million in 2024, then crashed by 46.49% to $170.7 million in 2025.
  • Per Business Quant, the three most recent readings for NTLA's Total Non-Current Liabilities are $170.7 million (Q4 2025), $319.1 million (Q4 2024), and $250.8 million (Q4 2023).